Towards Mechanism-based Treatments for Fragile X Syndrome

It has been more than 25 years since the identification of the FMR1 gene and the demonstration of the causative role of CGG-repeat expansion in the disease pathology of fragile X syndrome (FXS), but the underlying mechanisms involved in the expansion mutation and the resulting gene silencing still r...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Kumari, Daman, Gazy, Inbal
Формат: Online
Язык:английский
Опубликовано: MDPI - Multidisciplinary Digital Publishing Institute 2021
Предметы:
Online-ссылка:42526
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!
_version_ 1869518350588051456
author Kumari, Daman
Gazy, Inbal
author_browse Gazy, Inbal
Kumari, Daman
author_facet Kumari, Daman
Gazy, Inbal
author_sort Kumari, Daman
collection Directory of Open Access Books
description It has been more than 25 years since the identification of the FMR1 gene and the demonstration of the causative role of CGG-repeat expansion in the disease pathology of fragile X syndrome (FXS), but the underlying mechanisms involved in the expansion mutation and the resulting gene silencing still remain elusive. Our understanding of the pathways impacted by the loss of FMRP function has grown tremendously, and has opened new avenues for targeted treatments for FXS. However, the failure of recent clinical trials that were based on successful preclinical studies using the Fmr1 knockout mouse model has forced the scientific community to revisit clinical trial design and identify objective outcome measures. There has also been a renewed interest in restoring FMR1 gene expression as a possible treatment approach for FXS. This special issue of Brain Sciences highlights the progress that has been made towards understanding the disease mechanisms and how this has informed the development of treatment strategies that are being explored for FXS.
format Online
id doab-20.500.12854ir-61057
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-610572024-04-05T12:32:12Z Towards Mechanism-based Treatments for Fragile X Syndrome Kumari, Daman Gazy, Inbal QH301-705.5 Q1-390 n/a lymphoblast pluripotent stem cells FMR1 Gene editing X chromosome Fmr1 epigenetic gene silencing FMR1 gene Fragile X syndrome 1 repeat instability characteristics that have the greatest impact DNA instability working memory language development mosaicism CRISPR 3 clinical trials autism spectrum disorders Fmr1 KO mouse automated vocal analysis base excision repair (BER) inhibitory control cerebral spinal fluid iPSC drug development targeted treatments molecular biomarkers viral vector avoidance biomarker set-shifting early identification expansion anxiety planning voice of the person mismatch repair (MMR) gene reactivation double-strand break repair (DSBR) newborn screening intellectual disability processing speed voice of the patient fragile X syndrome adeno-associated virus neurodevelopmental disorders histone methylation Non-homologous end-joining (NHEJ) ASD Fxr2 Fragile X-associated Tremor/Ataxia Syndrome 2 Trinucleotide Repeat 4 CGG Repeat Expansion Disease DNA methylation contraction fragile X mental retardation protein RNA:DNA hybrid behavior developmental disorders cognition females FMRP Fragile X Syndrome unstable repeat diseases protein synthesis brain cognitive flexibility treatment development fibroblast PRC2 transcription coupled repair (TCR) best practices attention Fragile X executive function thema EDItEUR::P Mathematics and Science::PS Biology, life sciences It has been more than 25 years since the identification of the FMR1 gene and the demonstration of the causative role of CGG-repeat expansion in the disease pathology of fragile X syndrome (FXS), but the underlying mechanisms involved in the expansion mutation and the resulting gene silencing still remain elusive. Our understanding of the pathways impacted by the loss of FMRP function has grown tremendously, and has opened new avenues for targeted treatments for FXS. However, the failure of recent clinical trials that were based on successful preclinical studies using the Fmr1 knockout mouse model has forced the scientific community to revisit clinical trial design and identify objective outcome measures. There has also been a renewed interest in restoring FMR1 gene expression as a possible treatment approach for FXS. This special issue of Brain Sciences highlights the progress that has been made towards understanding the disease mechanisms and how this has informed the development of treatment strategies that are being explored for FXS. 2021-02-12T06:10:59Z 2021-02-12T06:10:59Z 2019-12-09 11:49:15 2019 book 42526 9783039215065 9783039215058 https://directory.doabooks.org/handle/20.500.12854/61057 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/1554 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03921-506-5 10.3390/books978-3-03921-506-5 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039215065 9783039215058 250 open access
spellingShingle QH301-705.5
Q1-390
n/a
lymphoblast
pluripotent stem cells
FMR1
Gene editing
X chromosome
Fmr1
epigenetic gene silencing
FMR1 gene
Fragile X syndrome 1
repeat instability
characteristics that have the greatest impact
DNA instability
working memory
language development
mosaicism
CRISPR 3
clinical trials
autism spectrum disorders
Fmr1 KO mouse
automated vocal analysis
base excision repair (BER)
inhibitory control
cerebral spinal fluid
iPSC
drug development
targeted treatments
molecular biomarkers
viral vector
avoidance
biomarker
set-shifting
early identification
expansion
anxiety
planning
voice of the person
mismatch repair (MMR)
gene reactivation
double-strand break repair (DSBR)
newborn screening
intellectual disability
processing speed
voice of the patient
fragile X syndrome
adeno-associated virus
neurodevelopmental disorders
histone methylation
Non-homologous end-joining (NHEJ)
ASD
Fxr2
Fragile X-associated Tremor/Ataxia Syndrome 2
Trinucleotide Repeat 4
CGG Repeat Expansion Disease
DNA methylation
contraction
fragile X mental retardation protein
RNA:DNA hybrid
behavior
developmental disorders
cognition
females
FMRP
Fragile X Syndrome
unstable repeat diseases
protein synthesis
brain
cognitive flexibility
treatment development
fibroblast
PRC2
transcription coupled repair (TCR)
best practices
attention
Fragile X
executive function
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
Kumari, Daman
Gazy, Inbal
Towards Mechanism-based Treatments for Fragile X Syndrome
title Towards Mechanism-based Treatments for Fragile X Syndrome
title_full Towards Mechanism-based Treatments for Fragile X Syndrome
title_fullStr Towards Mechanism-based Treatments for Fragile X Syndrome
title_full_unstemmed Towards Mechanism-based Treatments for Fragile X Syndrome
title_short Towards Mechanism-based Treatments for Fragile X Syndrome
title_sort towards mechanism based treatments for fragile x syndrome
topic QH301-705.5
Q1-390
n/a
lymphoblast
pluripotent stem cells
FMR1
Gene editing
X chromosome
Fmr1
epigenetic gene silencing
FMR1 gene
Fragile X syndrome 1
repeat instability
characteristics that have the greatest impact
DNA instability
working memory
language development
mosaicism
CRISPR 3
clinical trials
autism spectrum disorders
Fmr1 KO mouse
automated vocal analysis
base excision repair (BER)
inhibitory control
cerebral spinal fluid
iPSC
drug development
targeted treatments
molecular biomarkers
viral vector
avoidance
biomarker
set-shifting
early identification
expansion
anxiety
planning
voice of the person
mismatch repair (MMR)
gene reactivation
double-strand break repair (DSBR)
newborn screening
intellectual disability
processing speed
voice of the patient
fragile X syndrome
adeno-associated virus
neurodevelopmental disorders
histone methylation
Non-homologous end-joining (NHEJ)
ASD
Fxr2
Fragile X-associated Tremor/Ataxia Syndrome 2
Trinucleotide Repeat 4
CGG Repeat Expansion Disease
DNA methylation
contraction
fragile X mental retardation protein
RNA:DNA hybrid
behavior
developmental disorders
cognition
females
FMRP
Fragile X Syndrome
unstable repeat diseases
protein synthesis
brain
cognitive flexibility
treatment development
fibroblast
PRC2
transcription coupled repair (TCR)
best practices
attention
Fragile X
executive function
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
topic_facet QH301-705.5
Q1-390
n/a
lymphoblast
pluripotent stem cells
FMR1
Gene editing
X chromosome
Fmr1
epigenetic gene silencing
FMR1 gene
Fragile X syndrome 1
repeat instability
characteristics that have the greatest impact
DNA instability
working memory
language development
mosaicism
CRISPR 3
clinical trials
autism spectrum disorders
Fmr1 KO mouse
automated vocal analysis
base excision repair (BER)
inhibitory control
cerebral spinal fluid
iPSC
drug development
targeted treatments
molecular biomarkers
viral vector
avoidance
biomarker
set-shifting
early identification
expansion
anxiety
planning
voice of the person
mismatch repair (MMR)
gene reactivation
double-strand break repair (DSBR)
newborn screening
intellectual disability
processing speed
voice of the patient
fragile X syndrome
adeno-associated virus
neurodevelopmental disorders
histone methylation
Non-homologous end-joining (NHEJ)
ASD
Fxr2
Fragile X-associated Tremor/Ataxia Syndrome 2
Trinucleotide Repeat 4
CGG Repeat Expansion Disease
DNA methylation
contraction
fragile X mental retardation protein
RNA:DNA hybrid
behavior
developmental disorders
cognition
females
FMRP
Fragile X Syndrome
unstable repeat diseases
protein synthesis
brain
cognitive flexibility
treatment development
fibroblast
PRC2
transcription coupled repair (TCR)
best practices
attention
Fragile X
executive function
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
url 42526
work_keys_str_mv AT kumaridaman towardsmechanismbasedtreatmentsforfragilexsyndrome
AT gazyinbal towardsmechanismbasedtreatmentsforfragilexsyndrome